||Recombinant Human Interleukin 13 variant produced inE.coliis a mature 114 amino acid protein with a substitution of Q for R at position 112.
||IL-13 is an immunoregulatory cytokine produced primarily by activated Th2 cells, and also by mast cells and NK cells. Targeted deletion of IL-13 in mice resulted in impaired Th2 cell development and indicated an important role for IL-13 in the expulsion of gastrointestinal parasites. IL-13 exerts anti-inflammatory effects on monocytes and macrophages and it inhibits the expression of inflammatory cytokines such as IL-1β, TNF-α, IL-6 and IL-8. IL-13 has also been shown to enhance B cell proliferation and to induce isotype switching resulting in increased production of IgE. Blocking of IL-13 activity inhibits the pathophysiology of asthma. Human IL-13 is cross-species reactive. A variant of IL-13 shows enhanced functional activity compared with the wild type IL-13.
||> 98% (SDS-PAGE, HPLC).
||< 0.1 ng per ug of IL-13 Variant.
||This IL-13 analog shows a two fold increase, relative to wild type IL-13, in bioactivity as measured by the in-vitro dose dependent activation of STAT6 and IL-13 dependent gene induction in transfected A201.1 cells. This analog has also been shown to exhibit increased in vivo activity compared to wild type IL-13, as measured by the induction of airway hyper-responsiveness.
||The lyophilized protein is stable for at least 2 years from date of receipt at -20℃. Reconstituted humanIL-13 Variant is stable for at least 3 months when stored in working aliquots with a carrier protein at -20℃. Avoid repeated freeze-thaw cycles.